CD8A and influenza: Vaccine and immunotherapeutic strategies could leverage Qa-1/HLA-E–binding epitopes, such as those from CMV, influenza (M-SL9), or even SARS-CoV-2, to elicit complementary CD8+ T cell responses that bypass viral immune evasion.